S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in
NYSE:ZYME

Zymeworks Stock Forecast, Price & News

$51.47
-1.39 (-2.63 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$50.53
Now: $51.47
$53.42
50-Day Range
$47.08
MA: $52.34
$56.81
52-Week Range
$20.33
Now: $51.47
$59.03
Volume570,024 shs
Average Volume535,611 shs
Market Capitalization$2.36 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.75
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; collaboration with Applied BioMath, LLC.; and a research collaboration with ImmunoPrecise Antibodies Ltd. for the development of multiple antibody candidates to fight COVID-19. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Zymeworks logo

MarketRank

Overall MarketRank

1.39 out of 5 stars

Medical Sector

548th out of 1,928 stocks

Pharmaceutical Preparations Industry

272nd out of 774 stocks

Analyst Opinion: 2.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:ZYME
CUSIPN/A
Phone604-678-1388
Employees325

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.54 million
Book Value$6.21 per share

Profitability

Net Income$-145,440,000.00
Net Margins-569.13%

Miscellaneous

Market Cap$2.36 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable
$51.47
-1.39 (-2.63 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zymeworks (NYSE:ZYME) Frequently Asked Questions

How has Zymeworks' stock been impacted by COVID-19?

Zymeworks' stock was trading at $32.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZYME shares have increased by 59.5% and is now trading at $51.47.
View which stocks have been most impacted by COVID-19
.

Is Zymeworks a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Zymeworks stock.
View analyst ratings for Zymeworks
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Zymeworks?

Wall Street analysts have given Zymeworks a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zymeworks wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Thomas Greco's approval rating as Zymeworks' CEO?

538 employees have rated Zymeworks CEO Thomas Greco on Glassdoor.com. Thomas Greco has an approval rating of 63% among Zymeworks' employees. This puts Thomas Greco in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Zymeworks
.

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) announced its quarterly earnings results on Tuesday, November, 3rd. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.89) by $0.54. The company had revenue of $2.64 million for the quarter, compared to the consensus estimate of $12.13 million. Zymeworks had a negative net margin of 569.13% and a negative return on equity of 44.06%.
View Zymeworks' earnings history
.

What price target have analysts set for ZYME?

10 Wall Street analysts have issued 12 month price targets for Zymeworks' stock. Their forecasts range from $42.00 to $74.00. On average, they anticipate Zymeworks' share price to reach $58.44 in the next year. This suggests a possible upside of 13.6% from the stock's current price.
View analysts' price targets for Zymeworks
or view Wall Street analyst' top-rated stocks.

Are investors shorting Zymeworks?

Zymeworks saw a decline in short interest in December. As of December 31st, there was short interest totaling 874,600 shares, a decline of 25.9% from the December 15th total of 1,180,000 shares. Based on an average daily volume of 354,700 shares, the days-to-cover ratio is presently 2.5 days.
View Zymeworks' Short Interest
.

Who are some of Zymeworks' key competitors?

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group Inc. (JE.TO) (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

Who are Zymeworks' key executives?

Zymeworks' management team includes the following people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 49, Pay $902.94k)
  • Dr. Anthony J. Polverino, Chief Scientific Officer & Exec. VP of Early Devel. (Age 58, Pay $578.38k)
  • Ms. Kathryn O'Driscoll, Chief People Officer (Age 57, Pay $108.89k)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 58, Pay $646.51k)
  • Dr. Neil Josephson M.D., Sr. VP of Clinical Research
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA, Exec. VP of Bus. Operations & CFO (Age 49)
  • Dr. Surjit Dixit, VP of Technology (Age 48)
  • Mr. Daniel Dex, VP of Legal & Corp. Sec.
  • Mr. John Babcook, Sr. VP of Discovery Research (Age 58)
  • Mr. Mark Hollywood, Sr. VP of Technical & Manufacturing Operations (Age 52)

When did Zymeworks IPO?

(ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.37%) and Vigilare Wealth Management (0.01%). Company insiders that own Zymeworks stock include Ali Tehrani, David Kai Yuen Poon, Diana Hausman, Eli & Co Lilly, Neil A Klompas and Troy Cox.
View institutional ownership trends for Zymeworks
.

Which institutional investors are selling Zymeworks stock?

ZYME stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, and Vigilare Wealth Management. Company insiders that have sold Zymeworks company stock in the last year include Ali Tehrani, Diana Hausman, and Neil A Klompas.
View insider buying and selling activity for Zymeworks
or view top insider-selling stocks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $51.47.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $2.36 billion and generates $29.54 million in revenue each year. The company earns $-145,440,000.00 in net income (profit) each year or ($3.83) on an earnings per share basis. Zymeworks employs 325 workers across the globe.

What is Zymeworks' official website?

The official website for Zymeworks is www.zymeworks.com.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.